Introduction
tracting lipid levels in this fraction from levels in the d<1. 019 HDL to other lipoproteins in plasma from patients g/ml fraction. Cholesterol, free cholesterol, and triglycerides with chronic renal failure and hyperlipidaemia [9 ] . in serum and serum fractions were measured enzymatically Furthermore, plasma newly synthesized cholesteryl (kits from Boehringer Mannheim). LDL cholesterol was ester transfer (NCET ) activity is closely related to calculated using the Friedewald formula [11 ] . Serum apolipolevels of apoB in patients with chronic renal failure proteins A1 and B concentrations were measured by an [9 ] . The aim of the present study was, therefore, to immunoturbidimetric method [12 ] . NCET activity in serum determine whether treatment with an HMG CoA that had been stored at −80°C was measured by an isotopic reductase inhibitor reduces apoB-lipoprotein acceptor assay that uses endogenous lipoproteins [13] . Briefly, serum levels and serum NCET activity in patients with was incubated with a [3H] cholesterol-albumin emulsion for 3 h at 37°C and the appearance of labelled cholesteryl esters chronic renal failure receiving dialysis. The study was in precipitated VLDL and LDL was measured. Using serum part of a larger multicentre, double-blind, placebofree cholesterol concentration, the NCET rate was calculated.
controlled trial which examined the effect of treatment
The coefficient of variation for the assay was 10%. Previous with simvastatin or enalapril or both on left ventricular studies from this laboratory have shown that NCET activity mass and serum lipids and lipoproteins in patients with is similar in fresh or frozen (-80°C ) normolipidaemic or chronic renal failure.
hyperlipidaemic plasma and is closely related to net mass cholesteryl ester transfer in plasma measured by chemical methods [9] . Also, serum NCET activity was measured in
Patients and methods
10 fresh sera from one study centre (30.3±12.8 nmol/ml/h, n=10, mean±SD) and the activities were not significantly Patients different compared with values for the corresponding sera stored at −80°C (28.9±11.2 nmol/ml/h, n=10, mean±SD). The patients studied were drawn from a group of 107 patients Serum LCAT activity was measured by a modification of the (aged 18-75 years) with chronic renal failure treated by Stokke and Norum method [13 ] . haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) who were recruited into a multicentre study of the Statistics effect of therapy with simvastatin or enalapril or both on serum lipoprotein concentration and left ventricular mass.
Analyses were performed on the basis of intention-to-treat. Exclusion criteria included definite indication for HMG CoA Repeated measures ANOVA was used to compare the effects reductase inhibitor or angiotensin-converting enzyme ( ACE) of treatments. Student's t test was used to compare baseline inhibitor therapy, known allergy to either drug, planned values between patients treated by haemodialysis or CAPD. renal graft from living relative within 12 months, congestive
Pearson's product moment correlation coefficients were used heart failure, severe valve disease, supine systolic blood to test for relationships between variables. Partial correlation pressure <100 mmHg or significant postural hypotension, analysis was used to test relationships between two variables uncontrolled hypertension (>170/105 mmHg) hepatitis B or while a third variable was held constant. Two-tailed tests of C positive, AST or ALT>twice upper limit of normal, significance were used and a P value of less than 0.05 was treatment with cyclosporin or a fibrate, life-threatening illness considered to be statistically significant. or serious debilitating disease other than chronic renal failure, child-bearing potential without adequate contraception, and potential unreliability. Patients were screened, including a Results medical history and a physical examination with measurement of body weight and supine blood pressure. Patients who satisfied entry criteria were randomized in a factorial Mean (±SD) age, body mass index (BMI ) and duradesign to receive one of four treatments for 6 months: (a) tion of dialysis were 50±15 years, 25.3±4.4 kg/m2 simvastatin (10 mg daily) plus enalapril (2.5-5 mg daily) ( b) and 30±35 months respectively in the 53 subjects ( 32 simvastatin plus placebo enalapril (c) enalapril plus placebo men and 21 women) studied. The aetiology of renal simvastatin, and (d ) placebo enalapril plus placebo simvasta-failure in the patients was as follows: glomerulotin. The study was double-blinded and the code identifying nephritis (n=26, autosomal dominant polycystic the treatment received by individual patients was maintained kidney disease (n=6), reflux nephropathy (n=5), renal by a person remote from the investigators. The patients (n= vascular disease (n=6), diabetes (n=3), and other 53 ) in the present study were those for whom there was sufficient serum stored at −80°C to perform measurements causes (n=7). Twenty-five patients were receiving of plasma NCET activity and LCAT activity. Laboratory haemodialysis therapy and 28 patients were being measurements of serum lipids, lipoproteins and apolipo-treated by CAPD. Simvastatin therapy was disconprotein concentrations, NCET activity, and LCAT activity tinued in five patients and enalapril therapy was diswere performed at baseline and 6 months. continued in 16 patients before the end of the study. The study design allowed continuation of simvastatin Laboratory measurements or placebo treatment despite the withdrawal of enalapril or placebo enalapril.
Blood was collected in plain tubes after a 12-h fast. Serum
The effect of simvastatin treatment on serum NCET HDL cholesterol was measured in the supernatant after activity, LCAT activity, and lipid, lipoprotein and precipitation of apoB-containing lipoproteins with phosphoapolipoprotein concentrations during a 6-month tungstic acid and magnesium chloride [ 10] . Serum was follow-up are shown in Table 1 . Serum NCET activity ultracentrifuged at densities 1.006 g/ml and 1.019 g/ml.
and LCAT activity were reduced significantly with VLDL was isolated in the d<1.006 g/ml fraction and IDL cholesterol and IDL triglycerides were obtained by sub-simvastatin treatment. The effect of simvastatin on serum lipids lipoproteins, including decreases in total significantly compared with placebo in hyperlipidaemic patients. In contrast, the decrease in plasma NCET cholesterol, LDL cholesterol, and apoB concentrations were similar to the corresponding changes in the total activity in normolipidaemic dialysis patients treated with simvastatin was not significantly different comstudy population (n=107). Enalapril treatment did not significantly alter serum NCET and LCAT activit-pared with the change in NCET in the corresponding placebo group. The magnitude of the mean (±SD) ies and is not considered further in this report. Baseline values for variables were not significantly different decrease in serum NCET activity with simvastatin treatment was significantly (P=0.036) greater in hyperbetween the placebo group and the simvastatin group. Mean (±SD) BMI and serum creatinine concentration lipidaemic patients (−5.2±5.9 nmol/ ml/h) compared with normolipidaemic patients (−12.4±7.1 nmol/ were not significantly different between subjects treated with placebo (25.2±4.0 kg/m2, 0.97±0.27 mmol/l, n= ml/h). Levels of plasma cholesterol and apoB concentrations paralleled levels of variables in Table 2 (data 29 respectively) and those treated with simvastatin ( 25.4±5.0 kg/m2, 0.92±0.22 mmol/l, n=24 respect-not shown). Table 3 shows measured variables at baseline in ively) and did not change significantly during the study. There were no statistically significant effects of simvas-patients treated by haemodialysis or CAPD. Serum NCET activity, IDL cholesterol and apoB concentratatin on creatine kinase, ALT, urea, potassium, or haemoglobin.
tions were significantly higher in the CAPD patients and serum LCAT activity was higher and HDL choles- Table 2 shows serum NCET activity in normolipidaemic dialysis patients and hyperlipidaemic patients during treatment with simvastatin or placebo. terol
taining lipoprotein acceptor particles and reduced patients (29.5±7.6 nmol/ml/h, n=19) and hyperlipidaserum LCAT activity may be mainly responsible for emic CAPD patients ( 36.8±8.4 nmol/ml/h, n=16) the decrease in serum NCET activity in patients on compared with the corresponding normolipidaemic dialysis and treated with simvastatin. The decrease in patients (haemodialysis; 17.0±5.2 nmol/ml/h, n=13; serum NCET activity was closely and independently CAPD: 20.1±2.9 nmol/ml/h, n=5).
linked with the concomitant decreases in serum apoB Table 4 shows the effect of simvastatin treatment on concentration and LCAT activity during simvastatin serum NCET activity and LCAT activity in patients therapy and was no longer evident when these changes receiving haemodialysis or CAPD. The decrease in were taken into account. The decrease in serum apoB these activities with simvastatin treatment was not levels appeared to be more influential in this context significantly different between patients on haemodiabecause serum NCET activity still tended to decrease lysis compared with those on CAPD.
when LCAT activity but not when serum apoB concenAt baseline, serum NCET activity was correlated tration was taken into account. The present findings significantly with serum LCAT activity (r=0.605, n= seem to be consistent with a recent study which has 53, P<0.01) and serum concentrations of apoB (r= reported a decrease in plasma cholesteryl ester mass 0.842, n=53, P<0.001), cholesterol (r=0.559, n=53, transfer as a result of a decrease in LDL particle P<0.001) and triglycerides (r=0.724, n=53, P numbers in patients with familial hypercholesterolae-<0.001). The decrease in serum NCET activity in mia treated with pravastatin [2 ] . subjects treated with simvastatin (n=23) was correl-
The simvastatin-induced decrease in serum NCET ated significantly with the concomitant decreases in activity in the present study is also consistent with the LCAT activity (r=0.715, P<0.001) and apoB (r= reported fall in plasma NCET activity in patients with 0.715, P<0.001). The decrease in LCAT activity NIDDM treated with an HMG CoA reductase inhibduring this therapy was not correlated significantly itor [4 ] . However, in NIDDM patients, the decrease with the decrease in apoB (r=0.331). The decrease in in plasma NCET activity was attributed to a decrease serum NCET activity during treatment with simvasta-in the free cholesterol content of triglyceride-rich lipotin was not significant when serum LCAT activity (P= proteins [4 ] . On the other hand, increased free choles-0.07) or apoB concentration (P=0.14) or both (P= terol content of VLDL and LDL from patients with 0.64) were taken into account in two-way ANOVA. end-stage renal failure treated by haemodialysis has This decrease in serum NCET activity was not correl-been previously associated with low rates of cholesteryl ated significantly with duration of dialysis (r=−0.301, ester transfer [14 ] . Thus it seems unlikely that altered P=0.15).
lipoprotein free cholesterol content contributed to the present decrease in plasma NCET activity in patients on dialysis treated with simvastatin.
Discussion
Theoretically a decrease in serum NCET activity could be due to a decrease in CETP mass. In a previous The results of the present study show that treatment study, therapy with an HMG CoA reductase inhibitor with simvastatin substantially reduces serum NCET did not reduce plasma CETP mass in patients with activity and to a lesser extent serum LCAT activity, in familial hypercholesterolemia [2 ] . Thus, it is conceivassociation with a decrease in serum apoB-containing able that in the present study, CETP mass was also lipoproteins levels in patients with chronic renal failure unaffected by simvastatin treatment and did not medion dialysis. The magnitude of the decrease in serum ate the simvastatin-induced decrease in serum NCET NCET activity with simvastatin treatment was not activity which we observed. Nevertheless, the effect of influenced by the type of dialysis treatment used in the simvastatin therapy on circulating levels of CETP in patients with renal failure requires investigation. management of the patients but was greater in hyperli- Abbreviations are as shown in Table 1 . aSignificance associated with haemodialysis vs CAPD in two factor (simvastatin, type of dialysis) repeated measures analysis of variance.
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The fall in serum LCAT activity that we observed ester transfer may be linked with hyperapobetalipoproteinaemia in patients treated by CAPD [18 ] . in patients on dialysis treated with simvastatin conflicts with findings in a recent report [15] . Treatment with Plasma LCAT activities in the haemodialysis patients at baseline were comparable with the corresponding pravastatin, an HMG CoA reductase inhibitor with similar properties to simvastatin, did not affect plasma activities in haemodialysed uraemic patients and healthy controls reported by Bories and co-workers LCAT activity in patients with chronic renal failure receiving haemodialysis or CAPD [15 ] . The differing [19] but were markedly higher than values in haemodialysed patients reported by Dieplinger and findings between the two studies may relate to the method used to determine LCAT activity. Nishizawa co-workers [14] . Again, restricted dietary intake and low plasma lipid levels may underlie the low plasma and co-workers [15 ] used a 'common substrate' method [16 ] and this activity is independent of endogenous LCAT levels in haemodialysis patients in one of the previous studies [14 ] . In that study, plasma free choles-LCAT substrate and probably reflects plasma LCAT concentration. In contrast, we used a 'self substrate' terol levels were low ( mean, 1.0 mmol/l ), which in the light of the close correlation between molar LCAT rate method which is influenced by the effects of both endogenous substrate levels and concentration of and plasma free cholesterol levels in the literature [20 ] , may contribute to the low plasma LCAT activity in LCAT in serum. Thus, simvastatin therapy in patients with chronic renal failure may reduce LCAT activity the haemodialysis patients. In addition, a low-calorie diet is reported as reducing plasma LCAT activity [21 ] . by altering plasma lipoprotein levels and composition but not the concentration of the enzyme.
There are limitations to the present findings. The availability of suitably stored serum samples may have Abnormally low rates of plasma cholesteryl ester transfer and LCAT activity in patients with chronic introduced bias. However, given that the serum lipid values in Table 1 are similar to those for the total renal failure treated by haemodialysis and normal levels of these variables in those treated by CAPD study population, it is unlikely that this limitation affected the interpretation of our data. There were have been reported previously [14] . In contrast, baseline serum NCET activity in the present haemodialysis downward trends in serum cholesterol, LDL cholesterol, NCET activity, and LCAT activity in the placebo patients was not appreciably different from the activity in healthy subjects with comparable plasma lipid group, which may be due to changes in life-style and in particular diet during the study. Whether or not levels ( 22.1±7.9, n=27) and was higher than levels in a subgroup of these healthy subjects with plasma dialysis treatment contributed to these changes is uncertain. A previous study has reported that dialysis cholesterol <6.5 mmol/l and plasma triglycerides <2.0 mmol/l that we have reported in an earlier study does not alter plasma cholesterol levels but reduces plasma apoB levels during a 2-year period of therapy [9 ] . This apparent discrepancy might be explained by differences in plasma levels of lipids and apoB-con- [22] .
Increased plasma NCET activity independent of taining lipoproteins in particular, which are probably due to differences in dietary intake in patients between plasma lipids and LCAT activity in patients with angiographic evidence of coronary artery disease has the studies. In the study reported by Dieplinger and co-workers [14 ], plasma lipid levels were normal in the been documented previously [23 ] . Thus the reduced plasma NCET activity that we observed in dialysis CAPD patients and plasma cholesterol concentration was low (mean, 3.42 mmol/l ) in the patients treated patients during simvastatin therapy might conceivably be associated with reduced risk of coronary artery by haemodialysis. Also, body weight was low which suggests that dietary intake was restricted in these disease. Slow transfer of cholesteryl esters from HDL to atherogenic apoB-containing lipoproteins as well as dialysis patients. In contrast, body weight and serum lipid levels and undoubtedly serum levels of apoB-decreased levels of these lipoproteins during simvastatin therapy may delay the premature onset of atherocontaining lipoproteins were substantially higher in the corresponding groups of patients in the present study. sclerotic disease. On the other hand it is possible that decreased movement of cholesteryl esters into apoBFurthermore, serum NCET activity was markedly higher in patients with hyperlipidaemia compared with containing lipoproteins that are taken up by hepatic receptors may reduce the efficiency of reverse cholesthose who were normolipidaemic and serum NCET was correlated strongly with serum lipids and apoB terol transport from peripheral tissues including the artery wall. There is evidence that reverse cholesterol concentrations. These data suggest that the higher rates of cholesteryl ester transfer in the dialysis patients transport may be inefficient in dialysis patients.
Reversal of the normal cell to plasma cholesterol efflux we studied may be due to higher levels of apoBcontaining lipoproteins compared with patients in the between cultured fibroblasts and plasma from haemodialysis patients has been documented [14 ] . Also, we previous study [14] . ApoB-containing lipoproteins are acceptors of cholesteryl esters transferred from HDL have reported previously that plasma levels of HDL 3 , an effective acceptor of cell cholesterol in vitro [24] , and are an important determinant of plasma cholesteryl ester transfer rates [2, 17] . The strong correlation are low and are of abnormal composition in patients with chronic renal failure [25 ] . Furthermore, the net between serum NCET activity and apoB concentration and elevated levels of these variables in patients with transfer rate of radiolabelled cholesterol from red blood cells to HDL 3 in vitro is abnormally low in these CAPD in the current study are similar to our previous findings [9] and suggest that accelerated cholesteryl patients nearly all of whom were treated by dialysis 9. Corboy J, Sutherland WH, Walker RJ, Robertson MC, Cox [25 ] . It is possible that these abnormalities in factors 
